Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Dipti Talaulikar, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Maria J Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis, Jorge J Castillo

Research output: Contribution to journalReview articlepeer-review

6 Downloads (Pure)

Abstract

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.

Original languageEnglish
Article numbere433
Number of pages4
JournalHemaSphere
Volume4
Issue number4
DOIs
Publication statusPublished - Aug 2020

Fingerprint

Dive into the research topics of 'Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic'. Together they form a unique fingerprint.

Cite this